File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome

TitleAdipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome
Authors
Issue Date2006
PublisherAmerican Association for Clinical Chemistry, Inc. The Journal's web site is located at http://www.clinchem.org
Citation
Clinical Chemistry, 2006, v. 52 n. 3, p. 405-413 How to Cite?
AbstractBackground: Adipocyte fatty acid-binding protein (A-FABP) is traditionally thought to be a cytosolic fatty acid chaperone expressed in adipocytes. Mice with targeted disruption of the A-FABP gene exhibit a striking phenotype with strong protection from insulin resistance, hyperglycemia, and atherosclerosis. The clinical relevance of these findings remains to be confirmed. Methods: We used tandem mass spectrometry-based proteomic analysis to identify proteins secreted from adipocytes and present in human serum. We measured serum A-FABP concentrations in 229 persons (121 men and 108 women; age range, 33-72 years), including 100 lean [body mass index (BMI) <25 kg/m2] and 129 overweight/obese individuals (BMI >25 kg/m2) selected from a previous cross-sectional study. Results: A-FABP was released from adipocytes and was abundantly present in human serum. Mean (SD) circulating concentrations of A-FABP were significantly higher in overweight/obese than in lean persons [32.3 (14.8) vs 20.0 (9.8) μg/L; P < 0.001]. Age- and sex-adjusted serum A-FABP concentrations correlated positively (P < 0.005) with waist circumference, blood pressure, dyslipidemia, fasting insulin, and the homeostasis model assessment insulin resistance index. Moreover, we observed a significant increase in A-FABP concentrations corresponding with increases in the number of components of the metabolic syndrome (P < 0.05). Conclusions: A-FABP is a circulating biomarker closely associated with obesity and components of the metabolic syndrome, and measurement of serum concentrations of A-FABP might be useful for clinical diagnosis of obesity-related metabolic and cardiovascular disorders. © 2006 American Association for Clinical Chemistry.
Persistent Identifierhttp://hdl.handle.net/10722/68219
ISSN
2015 Impact Factor: 7.457
2015 SCImago Journal Rankings: 2.472
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXu, Aen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorXu, JYen_HK
dc.contributor.authorStejskal, Den_HK
dc.contributor.authorTam, Sen_HK
dc.contributor.authorZhang, Jen_HK
dc.contributor.authorWat, NMSen_HK
dc.contributor.authorWong, WKen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2010-09-06T06:02:30Z-
dc.date.available2010-09-06T06:02:30Z-
dc.date.issued2006en_HK
dc.identifier.citationClinical Chemistry, 2006, v. 52 n. 3, p. 405-413en_HK
dc.identifier.issn0009-9147en_HK
dc.identifier.urihttp://hdl.handle.net/10722/68219-
dc.description.abstractBackground: Adipocyte fatty acid-binding protein (A-FABP) is traditionally thought to be a cytosolic fatty acid chaperone expressed in adipocytes. Mice with targeted disruption of the A-FABP gene exhibit a striking phenotype with strong protection from insulin resistance, hyperglycemia, and atherosclerosis. The clinical relevance of these findings remains to be confirmed. Methods: We used tandem mass spectrometry-based proteomic analysis to identify proteins secreted from adipocytes and present in human serum. We measured serum A-FABP concentrations in 229 persons (121 men and 108 women; age range, 33-72 years), including 100 lean [body mass index (BMI) <25 kg/m2] and 129 overweight/obese individuals (BMI >25 kg/m2) selected from a previous cross-sectional study. Results: A-FABP was released from adipocytes and was abundantly present in human serum. Mean (SD) circulating concentrations of A-FABP were significantly higher in overweight/obese than in lean persons [32.3 (14.8) vs 20.0 (9.8) μg/L; P < 0.001]. Age- and sex-adjusted serum A-FABP concentrations correlated positively (P < 0.005) with waist circumference, blood pressure, dyslipidemia, fasting insulin, and the homeostasis model assessment insulin resistance index. Moreover, we observed a significant increase in A-FABP concentrations corresponding with increases in the number of components of the metabolic syndrome (P < 0.05). Conclusions: A-FABP is a circulating biomarker closely associated with obesity and components of the metabolic syndrome, and measurement of serum concentrations of A-FABP might be useful for clinical diagnosis of obesity-related metabolic and cardiovascular disorders. © 2006 American Association for Clinical Chemistry.en_HK
dc.languageengen_HK
dc.publisherAmerican Association for Clinical Chemistry, Inc. The Journal's web site is located at http://www.clinchem.orgen_HK
dc.relation.ispartofClinical Chemistryen_HK
dc.subject.meshAdipocytes - metabolismen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshBiological Markers - blooden_HK
dc.subject.meshBlood Pressureen_HK
dc.subject.meshDyslipidemias - blooden_HK
dc.subject.meshExtracellular Fluid - metabolismen_HK
dc.subject.meshFatty Acid-Binding Proteins - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInsulin - blooden_HK
dc.subject.meshInsulin Resistanceen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetabolic Syndrome X - blood - diagnosisen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshObesity - blood - diagnosisen_HK
dc.subject.meshProteome - analysisen_HK
dc.titleAdipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndromeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0009-9147&volume=52&spage=405&epage=413&date=2006&atitle=Adipocyte+fatty+acid-binding+protein+is+a+plasma+biomarker+closely+associated+with+obesity+and+metabolic+syndromeen_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.emailWang, Y: yuwanghk@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1373/clinchem.2005.062463en_HK
dc.identifier.pmid16423904-
dc.identifier.scopuseid_2-s2.0-33644545704en_HK
dc.identifier.hkuros115420en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644545704&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume52en_HK
dc.identifier.issue3en_HK
dc.identifier.spage405en_HK
dc.identifier.epage413en_HK
dc.identifier.isiWOS:000235674900009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f10001032322-
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridWang, Y=34973733700en_HK
dc.identifier.scopusauthoridXu, JY=8947805200en_HK
dc.identifier.scopusauthoridStejskal, D=7005865420en_HK
dc.identifier.scopusauthoridTam, S=7202037323en_HK
dc.identifier.scopusauthoridZhang, J=35504391800en_HK
dc.identifier.scopusauthoridWat, NMS=6602131754en_HK
dc.identifier.scopusauthoridWong, WK=12753634200en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats